Cerebral venous sinus thrombosis in users of four hormonal contraceptives: levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch

Contraception

Volumn 74, Issue 4, 2006, Pages 290-292

  Jick, Susan S ^a   Jick, Hershel ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral venous sinus thrombosis; Contraceptive patch; Incidence rate; Oral contraceptive; Rate ratio

Indexed keywords

CONTRACEPTIVE AGENT; DESOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CEREBRAL VENOUS SINUS THROMBOSIS; CLINICAL ARTICLE; CONTRACEPTION; FEMALE; HORMONAL CONTRACEPTION; HUMAN; INCIDENCE; LONGITUDINAL STUDY; OCCLUSIVE CEREBROVASCULAR DISEASE; ORAL CONTRACEPTION; OUTCOMES RESEARCH; RISK ASSESSMENT; VEIN THROMBOSIS;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL, HORMONAL; DESOGESTREL; FEMALE; HUMANS; INTRACRANIAL THROMBOSIS; LEVONORGESTREL; NORGESTREL; RISK; SINUS THROMBOSIS, INTRACRANIAL;

EID: 33748561475     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2006.05.071     Document Type: Article

References (13)

1. Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
2. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 346 (1995) 1582-1588
3. Bloemenkamp K.W.M., Rosendaal F.R., Helmerhorst F.M., Büller H.R., and Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
4. Jick H., Kaye J.A., Vasilakis-Scaramozza C., and Jick S.S. Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 321 (2000) 1190-1195
5. Petitti D.B. Combination estrogen-progestin oral contraceptives. N Engl J Med 349 (2003) 1443-1450
6. Gomes M.P.V., and Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy. A clinical review. Arch Intern Med 164 (2004) 1965-1976
7. Vasilakis-Scaramozza C., and Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358 (2001) 1427-1429
8. Lawson D.H., Davidson J.F., and Jick H. Oral contraceptive use and venous thromboembolism: absence of an effect of smoking. BMJ 2 (1977) 729-730
9. Vessey M.P., and Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ 2 (1968) 199-205
10. Sartwell P.E., Masi A.T., Arthes F.G., et al. Thromboembolism and oral contraceptives: an epidemiologic case-control study. Am J Epidemiol 90 (1969) 365-380
11. de Bruijn S.F.T.M., Stam J., Koopman M.M.W., and Vandenbrouke J.P. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 316 (1998) 589-592
12. Martinelli I., Sacchi E., Landi G., et al. High risk of cerebral-vein-thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 338 (1998) 1793-1797
13. Jick S.S., Kaye J.A., Russmann S., and Jick H. Risk of non-fatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 73 (2006) 223-228